Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

NCT07206043 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: RPH-104 80 mg
BIOLOGICAL: RPH-104 160 mg
BIOLOGICAL: RPH-104 320 mg
BIOLOGICAL: RPH-104 320 mg
BIOLOGICAL: RPH-104 80 mg
BIOLOGICAL: RPH-104 80 mg
DRUG: Placebo

Sponsor

R-Pharm International, LLC

Collaborators

[object Object]
[object Object]